Table 3.

Cardiovascular endpoints in studies of selective COX2 inhibitors

Drug (reference)	Study	Aspirin allowed	CV endpoints	Hazard ratios or incidence of CV endpoints
				All	No aspirin	On aspirin
Rofecoxib (Bombardier 2000)	VIGOR	No	MI	4.25 (1.39−17.37)	Idem	Excluded
			CV death	c0.2% vs 0.2%, NS	Idem	Excluded
Celecoxib (Silverstein 2000)	CLASS	Yes	MI, stroke or angina	0.9% vs 1.0%, NS	0.5% vs 0.4%, NS	nr
Etoricoxib (Cannon 2006; Laine 2007)	MEDAL	Stimulated	aAny thrombotic events	0.95 (0.81−1.11)	d1.0% vs 1.0%, NS	d1.67% vs 1.87%, NS
			aArterial thrombotic events	0.96 (0.81−1.13)	nr	nr
			a,bAPTC (all MI, stroke or vascular death)	0.96 (0.79−1.16)	nr	nr
Lumiracoxib (Schnitzer 2004; Farkouh 2004)	TARGET	Yes	bAPTC (all MI, stroke or vascular death)
			vs ibuprofen + naproxen	1.14 (0.78–1.66)	1.22 (0.74–2.02)	1.04 (0.59–1.84)
			vs ibuprofen	0.76 (0.41–1.40)	0.94 (0.44–2.04)	0.56 (0.20–1.54)
			vs naproxen	1.46 (0.89–2.37)	1.49 (0.76–2.92)	1.42 (0.70–2.90)
			Confirmed or probable MI (clinical and silent)
			vs ibuprofen + naproxen	1.31 (0.70–2.45)	1.47 (0.63–3.39)	1.14 (0.44–2.95)
			vs ibuprofen	0.66 (0.21–2.09)	0.75 (0.20–2.79)	0.47 (0.04–5.14)
			vs naproxen	1.77 (0.82–3.84)	2.37 (0.74–7.55)	1.36 (0.47–3.93)

^aPer-protocol analysis, similar results after ITT analysis.

^bAPTC, Anti-Platelet Trialists' Collaboration endpoint.

^cincidence.

^devents per 100 patient yrs.

Abbreviations: nr, not reported.